Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › PGHL

PGHL

Procter & Gamble Health Limited
Micro-capPharma ↗

What the six lenses say about PGHL — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹5667.0
2026-09-08
VWAP · 1Y anchor
₹5753
-1.5% from VWAP
P/E · TTM
—
no TTM EPS
52-week range
42%
position low→high
RSI(14)
35
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How PGHL’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.0
avg conviction decile
Leadership
—
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD440›

The actual numbers

Price vs VWAP (1y)-1.5%
EMA trend stackMixed
Price vs 200-EMA-1.6%
Price vs 50-EMA-5.7%
RSI(14)35
RS vs Nifty 500 · 3M-13.0%
RS vs sector · 3M-19.1%
52-week range42%
Volume vs 30d avg0.27×
Volume vs 60d avg0.27×
ATR(14) · volatility144.4
Bollinger width · vol contraction0.067
FundamentalD437›

The actual numbers

Operating margin27.5%
Net margin20.4%
Revenue growth · YoY-6.3%
EPS growth · YoY+4.3%

Full 8-quarter history in the financials table below.

ValuationD532›

The actual numbers

52-week range42%
CatalystD119›

The actual numbers

Earnings & momentum21
Capital actions9
Governance32

Every filing in the corporate-announcements panel below.

FlowD858›

The actual numbers

Promoter holding51.8%
Delivery · 30d avg57.3%
Up/down-day asymmetry3.4pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D4 + D8 ) ÷ 2 = 6.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Watch
42
Conviction score 42/100 · avg-decile strength 6.0/10
Conviction score42/100›
TechnicalD4›
FundamentalD4›
ValuationD5›
CatalystD1›
FlowD8›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+0.6pp
-0.5pp
-3.1pp
-11.4pp
+18.7pp
-6.6pp
Nifty 500
Broad-market baseline
+0.5pp
-0.5pp
-4.2pp
-13.0pp
+12.9pp
-11.8pp
Sector
Own-sector index
—
—
-7.0pp
-19.1pp
-0.2pp
-32.6pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

PGHL daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
5667.00+7.00

Relative strength

RS vs baseline · rebased to 100

PGHL ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
111.57+0.61

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

No quarterly financials available.

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 4 Sep '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Aug '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 6 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 15 Jul '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 Jun '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Jun '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Jun '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Jun '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Jun '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 18 Jun '26
    MEDIUMearnings
    Investor Presentation
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 4 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 May '26
    MEDIUMcapital
    Press Release
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 26 May '26
    MEDIUMgovernance
    Appointment
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 26 May '26
    MEDIUMcapital
    Dividend
    ›

    A dividend declaration — a cash return to shareholders.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds PGHL

Mutual funds holding PGHL (10)

FundWeightAUM ₹crGrade
Nippon India Small Cap Gr Bns0.58%78,957
Nippon India Small Cap Dir Bns0.58%78,957
Nippon India Small Cap Gr0.58%78,957
DSP Healthcare Fund Reg Gr2.89%3,639
Bajaj Finserv Small Cap Reg Gr0.72%2,364
Tata India Pharma & Healthcare Reg Gr2.42%1,541
UTI Healthcare Reg Gr2.41%1,371
Aditya BSL Pharma & Hlthcare Reg Gr2.16%1,074
WhiteOak Capital Phrm and Hlthcr Reg Gr1.70%825
Baroda BNP P Hlth and Wellness RegGr0.64%519

ETFs holding PGHL (0)

No tracked ETF holds PGHL ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma